Evidence map›Paper›PMID 40600990›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Resveratrol alters erlotinib pharmacokinetics in rats: application of a rapid HPLC-fluorescence method for quantifying erlotinib in plasma.

Aref L Zayed, Jomana Al Hroot, Ruba S Darweesh, Nidal A Qinna, Aysheh M Alshekhhossin, Omar M Al Kilani

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aref L ZayedDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan. alzayed@just.edu.jo.
Jomana Al HrootDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Ruba S DarweeshDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Nidal A QinnaUniversity of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, 11196, Jordan.
Aysheh M AlshekhhossinDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Omar M Al KilaniDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResveratrol is a natural compound and commonly used dietary supplement, especially for its anticancer properties. However, there is a lack of pharmacokinetic (PK) studies investigating its interactions with anticancer drugs, including tyrosine kinase inhibitors (TKIs). This study aimed to investigate the effect of resveratrol on erlotinib pharmacokinetics, a TKI indicated for non-small-cell lung cancer (NSCLC). Another aim was to develop and validate a new high-performance liquid chromatography with fluorescence detection (HPLC-FLD) method as a simple and cost-effective assay to quantify erlotinib levels in rat plasma in vivo.

methodsHPLC-FLD was used to develop and validate a method for quantifying erlotinib in rat plasma. A PK study was conducted with four groups of male Sprague-Dawley rats: erlotinib (20 mg/kg) alone, erlotinib with either single or multiple doses of resveratrol (100 mg/kg), and a control group. Blood samples were collected and analyzed by HPLC-FLD, and the PK parameters were estimated.

resultsA 4-min runtime HPLC-FLD method was developed and validated. Single and multiple doses of resveratrol significantly increased the total area under the curve

conclusionResveratrol, even at a single dose, can alter erlotinib pharmacokinetics which may cause clinically relevant drug interactions, particularly considering erlotinib significant interindividual variability and narrow therapeutic index. The new HPLC-FLD method is a reliable, simple, and cost-effective assay that can be used in erlotinib PK studies and therapeutic drug monitoring.

Indexed as

Antineoplastic AgentsErlotinib HydrochlorideProtein Kinase InhibitorsResveratrolStilbenesAnimalsChromatography, High Pressure LiquidDrug InteractionsFluorescenceMaleRatsRats, Sprague-DawleyReproducibility of ResultsAntineoplastic AgentsErlotinib HydrochlorideProtein Kinase InhibitorsResveratrolStilbenesDrug interactionErlotinibFluorescenceHPLCResveratrol

Identifiers

PMID40600990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.